Category: Kinch Publications
Michael S. Kinch, Zachary Kraft, & Tyler Schwartz (2020). “Sources of innovation for new medicines: questions of sustainability” Drug Discov Today. 2020 Nov 2;S1359-6446(20)30443-8. doi: 10.1016/j.drudis.2020.10.026. Online ahead of print. (Abstract)
Michael Kinch (2019). “The End of the Beginning: Cancer, Immunity, and the Future of a Cure” ISBN-13: 978-1643130255, ISBN-10: 1643130250
Griesenauer R.H., Schillebeeckx C., & Kinch M.S. (2019). “Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases.” Drug Discov Today. 2019 Jan 25. pii: S1359-6446(18)30258-7. doi: 10.1016/j.drudis.2019.01.010. [Epub ahead of print] (Abstract)
Kinch M.S. & Griesenauer R.H. (2018). “2017 in review: FDA approvals of new molecular entities.” Drug Discov Today. 2018 May 8. pii: S1359-6446(18)30088-6. doi: 10.1016/j.drudis.2018.05.011. (Abstract)
Michael Kinch (2018). “Between Hope and Fear: A History of Vaccines and Human Immunity” ISBN-13: 978-1681777511, ISBN-10: 1681777517
Griesenauer R.H., Moore R., & Kinch M.S. (2017). “NIH Support for FDA-Approved Medicines.” Cell Chem Biol. 2017 Nov 16;24(11):1315-1316. doi: 10.1016/j.chembiol.2017.11.002. (Abstract)
Griesenauer R.H. & Kinch M.S. (2017). “An overview of FDA-approved vaccines & their innovators.” Expert Rev Vaccines. 2017 Dec;16(12):1253-1266. doi: 10.1080/14760584.2017.1383159. Epub 2017 Sep 25. (Abstract)
Griesenauer R.H. and Kinch M.S. (2017). “2016 in review: FDA approvals of new molecular entities.” Drug Discov Today. 2017 Nov;22(11):1593-1597. doi: 10.1016/j.drudis.2017.06.011. Epub 2017 Jul 4. (Abstract)
Green J.M., Barratt M.J., Kinch M., and Gordon J.I. (2017) “Food and microbiota in the FDA regulatory framework.” Science. 2017 Jul 7;357(6346):39-40. doi: 10.1126/science.aan0836. (Abstract)
Kinch M.S. and Woodard P.K. (2017) “Analysis of FDA-approved imaging agents.” Drug Discov Today. 2017 Jul;22(7):1077-1083. doi: 10.1016/j.drudis.2017.03.006. Epub 2017 Mar 21. (Abstract)